For patients  /  Lupus
Lupus condition hub

Lupus clinical trials, explained for patients.

How trials work, what eligibility rules actually mean, what's new in lupus research this year, and where to find support along the way. Built with resources from Lupus Canada and the lupus community.

Free, private, no obligation. Purple is the international colour of lupus awareness, so this page wears it too.

Reasons for hope

What's new in lupus research this year

Lupus research is moving. Three developments from 2026 worth knowing about, in plain language:

Phase 1 · OUTRACE SLE study

CLN-978 — Immune Cell Matchmaker

Early remission data presented at EULAR 2026

An experimental medicine that works by directing the immune system's own T-cells — the cells that normally fight infections — to find and clear the cells that are causing lupus to flare. In people whose lupus hadn't responded to other treatments, some reached remission after just a single dose.

Cullinan Therapeutics data from EULAR 2026 →
Phase 2 · WILLOW study

Enpatoran

Results published in The Lancet, May 2026

A first-of-its-kind oral pill that showed strong effectiveness for lupus patients with skin involvement. A pill matters: many current lupus treatments require infusions or injections.

Monash University research summary →
Phase 3 · AMETHYST trial

Litifilimab

FDA Breakthrough Therapy Designation, January 2026

A lab-made medicine designed to target one specific part of the immune system — developed for the form of lupus that mainly affects the skin, which still has no treatments specifically approved for it. The breakthrough designation means the FDA will actively help speed up its development and review process.

Lupus Research Alliance announcement →
The basics

How lupus clinical trials work

Clinical trials move through phases, and each one tests something different before a treatment can reach patients broadly:

Phase 1 Roughly 20–100 people

A small group — often including healthy volunteers alongside people with lupus — tests safety, tolerability, and dosing. It's the first time the treatment is given to people.

Phase 2 100–300 people with lupus

Tests whether the treatment actually works, while continuing to monitor safety and side effects.

Phase 3 300 to several thousand

A large, diverse group confirms effectiveness, often comparing the new treatment to a standard treatment or placebo. Usually the step required before regulatory approval.

Phase 4 After approval

The treatment is monitored in real-world use for long-term safety and rare side effects.

In every phase, three things stay constant: an informed consent process (a full explanation of purpose, risks, and benefits before you agree to participate), regular monitoring visits, and your right to withdraw at any time.
Decoding the fine print

What eligibility criteria mean

Every trial lists two kinds of rules. Here's how to read them:

Inclusion criteria

Traits most trials require you to have
  • A confirmed lupus diagnosis
  • A certain disease activity level
  • A specific age range
  • Specific prior treatments

Exclusion criteria

Traits that might rule you out of a specific trial
  • Certain other health conditions
  • Certain current medications
  • Pregnancy
  • Lab values outside a safe range
Worth repeating: these rules exist to protect participant safety and to keep the study's results reliable. They are not a judgment on you, and not qualifying for one trial doesn't mean you won't qualify for another.
You're not doing this alone

Trusted lupus resources

Support for the whole journey: learning, funding, and community.

Learn from Lupus Canada

Lupus Canada is our trusted partner — their free resources are among the best patient guides available.

Financial support

Help with medication and treatment costs

Community & emotional support

Canadian and American resources for patients, caregivers, and families

Not sure where to start? Talk to an expert.

Both organizations can answer questions and direct you to the right resources or trial opportunities.

CANADA Lupus Canada 1-800-661-1468 info@lupuscanada.org
US Lupus Foundation of America 1-800-558-0121
Before your first call

Tips for getting started

  • Found something on MyTrials that looks right? Your next step is your rheumatologist. Print or share the trial details and ask: "Is this worth exploring for me?" Doctors take patient-initiated trial questions seriously, and yours knows your history.
  • Contact the trial team with your information ready: your current medications, recent lab results, and a brief history of treatments you've tried. That's the first thing every coordinator asks for.
  • Use the tools below before your first call. The prep sheet, checklist, and consent guide were built for exactly this moment. Good trial teams expect these questions.

The 9-question checklist

The questions to ask any trial team before joining, with space to write their answers.

Download

Appointment prep sheet

One page to organize your medications, history, and questions before a screening visit.

Download

Consent form review sheet

A guided worksheet for reading a consent document at home before signing anything.

Download
The research updates and resources on this page are for information only and are not medical advice. Always talk to a rheumatologist before enrolling in any trial.

See which lupus trials fit your situation

Answer a few questions about your lupus, your treatments, and where you live. We'll show you what's recruiting, in plain language.

Free for patients. Private. No obligation at any step.